These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34608628)

  • 41. Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records.
    Villanueva V; Laloyaux C; D'Souza W; Faught E; Klein P; Reuber M; Rosenow F; Salas-Puig J; Insuga VS; Strzelczyk A; Szaflarski JP; Chinn C; Daniels T; Floricel F; Friesen D; Sendersky V; Besson H; Steinhoff BJ
    CNS Drugs; 2023 Sep; 37(9):819-835. PubMed ID: 37684497
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
    Yates SL; Fakhoury T; Liang W; Eckhardt K; Borghs S; D'Souza J
    Epilepsy Behav; 2015 Nov; 52(Pt A):165-8. PubMed ID: 26432008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
    Steinhoff BJ; Klein P; Klitgaard H; Laloyaux C; Moseley BD; Ricchetti-Masterson K; Rosenow F; Sirven JI; Smith B; Stern JM; Toledo M; Zipfel PA; Villanueva V
    Epilepsy Behav; 2021 May; 118():107939. PubMed ID: 33839453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany.
    Willems LM; Bertsche A; Bösebeck F; Hornemann F; Immisch I; Klein KM; Knake S; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; von Podewils F; Reif PS; Steinhoff BJ; Steinig I; Rosenow F; Schubert-Bast S; Strzelczyk A
    Front Neurol; 2018; 9():569. PubMed ID: 30083127
    [No Abstract]   [Full Text] [Related]  

  • 45. Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam.
    Schoemaker R; Krauwinkel W; Elshoff JP; Stockis A
    Epilepsy Res; 2024 May; 202():107332. PubMed ID: 38518434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients with epilepsy: An open-label trial.
    Farkas MK; Kang H; Fogarasi A; Bozorg A; James GD; Krauwinkel W; Morita D; Will E; Elshoff JP
    Epilepsia; 2022 Apr; 63(4):855-864. PubMed ID: 35196395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis.
    Lattanzi S; De Maria G; Rosati E; Didato G; Chiesa V; Ranzato F; Canafoglia L; Cesnik E; Anzellotti F; Meletti S; Pauletto G; Nilo A; Bartolini E; Marino D; Tartara E; Luisi C; Bonanni P; Marrelli A; Stokelj D; Dainese F
    Epilepsia; 2021 Jan; 62(1):e1-e6. PubMed ID: 33314118
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures.
    Toledo M; Whitesides J; Schiemann J; Johnson ME; Eckhardt K; McDonough B; Borghs S; Kwan P
    Epilepsia; 2016 Jul; 57(7):1139-51. PubMed ID: 27265725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial.
    Toledo M; Brandt C; Quarato PP; Schulz AL; Cleveland JM; Wagener G; Klein P
    Epilepsy Behav; 2021 May; 118():107897. PubMed ID: 33780735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brivaracetam add-on treatment in pediatric patients with severe drug-resistant epilepsy: Italian real-world evidence.
    Russo A; Pruccoli J; Cesaroni CA; Belotti LMB; Zenesini C; Bonanni P; Boni A; Cesaroni E; Coppola G; Cordelli DM; Danieli A; Mancardi MM; Marchese F; Matricardi S; Messana T; Nocera GM; Operto FF; Pellino G; Reina F; Vanadia F; Verrotti A; Striano P
    Seizure; 2022 Nov; 102():120-124. PubMed ID: 36223675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid switching from levetiracetam to brivaracetam in pharmaco-resistant epilepsy in people with and without intellectual disabilities: a naturalistic case control study.
    Watkins LV; Dunstall H; Musicha C; Lawthom C; John K; Bright C; Richings C; Harding K; Moon S; Pape SE; Winterhalder R; Allgar V; Thomas RH; McLean B; Laugharne R; Shankar R
    J Neurol; 2023 Dec; 270(12):5889-5902. PubMed ID: 37610448
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brivaracetam in the treatment of epilepsy: a review of clinical trial data.
    Feyissa AM
    Neuropsychiatr Dis Treat; 2019; 15():2587-2600. PubMed ID: 31571877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial.
    Klein P; McLachlan R; Foris K; Nondonfaz X; Elmoufti S; Dimova S; Brandt C
    Epilepsy Res; 2020 Nov; 167():106369. PubMed ID: 32717713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.
    Klein P; Schiemann J; Sperling MR; Whitesides J; Liang W; Stalvey T; Brandt C; Kwan P
    Epilepsia; 2015 Dec; 56(12):1890-8. PubMed ID: 26471380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity.
    Szaflarski JP; Sadek A; Greve B; Williams P; Varner JA; Moseley BD
    Epilepsy Behav; 2020 Aug; 109():107127. PubMed ID: 32417382
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open-label, single-arm study.
    Pressler R; Boylan G; Dempsey E; Klotz KA; Krauwinkel W; Will E; Morita D; Floricel F; Elshoff JP; van den Anker J
    Epilepsia Open; 2024 Apr; 9(2):522-533. PubMed ID: 38049197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.
    Ben-Menachem E; Mameniškienė R; Quarato PP; Klein P; Gamage J; Schiemann J; Johnson ME; Whitesides J; McDonough B; Eckhardt K
    Neurology; 2016 Jul; 87(3):314-23. PubMed ID: 27335114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.
    Klein P; Biton V; Dilley D; Barnes M; Schiemann J; Lu S
    Epilepsia; 2016 Jul; 57(7):1130-8. PubMed ID: 27221208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.